A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
NCT03509636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 113
Last updated 2022-07-01
Summary
This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP 1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer.
Conditions
Interventions
- DRUG
-
Fluzoparib
Fluzoparib capsule will be given twice daily orally
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-04
- Primary Completion
- 2019-08-26
- Completion
- 2020-07-23
Countries
- China
Study Locations
More Related Trials
-
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05613088 ·Status: COMPLETED ·Phase: PHASE2
-
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
NCT06161272 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
NCT05551208 ·Status: RECRUITING ·Phase: PHASE2
-
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
NCT05206890 ·Status: RECRUITING
-
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT05597527 ·Status: UNKNOWN ·Phase: PHASE2
-
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
NCT05753826 ·Status: RECRUITING ·Phase: PHASE2
-
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
NCT06539091 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
NCT04718740 ·Status: COMPLETED ·Phase: PHASE1
-
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
NCT03933761 ·Status: WITHDRAWN ·Phase: PHASE2
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
NCT06552858 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
NCT04229615 ·Status: UNKNOWN ·Phase: PHASE3
-
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
NCT05170594 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
NCT06107868 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
NCT03063710 ·Status: NO_LONGER_AVAILABLE
-
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
NCT06954584 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
NCT02631876 ·Status: COMPLETED ·Phase: PHASE3
-
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
NCT04417192 ·Status: COMPLETED ·Phase: PHASE2
-
Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting
NCT05153603 ·Status: UNKNOWN
-
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
NCT07060365 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
NCT04517357 ·Status: COMPLETED ·Phase: PHASE2